Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A randomized Phase III clinical trial found decitabine improved treatment outcomes for myelodysplastic syndrome patients, achieving a 17% complete response rate. The median time to progression was also significantly longer in treated patients compared to those receiving supportive care.
Researchers found decitabine improves disease-free periods, quality of life in MDS patients. New drug offers little survival benefit but improves quality of life and has some quality of life benefits compared to supportive care.
Researchers found PDT to be highly effective against drug-resistant bacteria and fungus, including S. mutans and Candida species, with minimal doses of light required to kill nearly all organisms.
Researchers developed a new way to study proteins in live cells, identifying interactions between Src and CrkL, and direct evidence of its role in MAP kinase pathways. This approach may lead to the development of new cancer treatments, such as targeting tyrosine kinases like Gleevec.
Duke University scientists increased chemotherapy drug molecular weight to improve tumor penetration and concentration while reducing healthy tissue toxicity. The optimal molecular weight range was found to be between 40,000 and 70,000.
A cancer researcher is working on a targeted way to deliver drugs to specific cells, making treatment more precise and effective. The approach uses natural biomolecules to target diseased cells while leaving healthy ones alone.
Rice University's bioengineering Ph.D. students will receive comprehensive training in cancer biology, clinical medicine, and translational research through a unique partnership with MD Anderson. The program aims to revolutionize the translation of cancer knowledge into new technologies for detection and treatment.
A new MRI drug, mangafodipir, has been found to improve the effectiveness of chemotherapy by increasing antitumoral activity while protecting normal cells from damage. The study suggests that mangafodipir may enhance the therapeutic index of anticancer agents and supports investigation into its use in cancer patients.
Parallel administration of chemotherapy and darbepoetin alfa every 3 weeks is safe and effective in treating anemia. Gene expression profiling may provide more accurate information for certain high-risk breast cancers than laboratory examination alone.
Researchers have identified small molecules called indoxins that can potentiate the effectiveness of doxorubicin in E6-expressing colon cancer cells. The compounds drive two distinct cell cycle-related mechanisms, overcoming E6-induced drug resistance and increasing sensitivity to chemotherapy.
Cedars-Sinai researchers discovered a biochemical pathway that makes gliomas and other cancer cells more sensitive to TRAIL, a protein inducing apoptosis in cancer cells. By combining TRAIL with pioglitazone, a diabetes drug, they aim to enhance the effectiveness of therapies targeting cancer cells.
Researchers believe that understanding the structure of DNA end caps, called telomeres, can help develop new cancer treatments. They found that the rate of shortening is influenced by the length of the overhang and hope to manipulate it for therapeutic purposes.
A study has found that vaginal oestrogen can increase systemic oestradiol levels in women on aromatase inhibitors (AI) for breast cancer, potentially counteracting AI treatment. Researchers recommend avoiding the combination of AIs and vaginal oestrogens, except in exceptional circumstances.
Researchers have developed a 'nanoshuttle' that uses viral particles to precisely home to disease, where it can perform various functions such as destroying tissue or emitting signals. The system has the potential to deliver stem cells to damaged areas, potentially treating heart disease and cancer.
The Vilcek Foundation honors Dr. Massagué's work on controlling cell behavior and its connection to cancer development. The prize recognizes his contributions to the field of cancer biology and genetics.
Researchers have identified a growth control flaw in some aggressive breast cancers, linked to overactive cyclin D1 and CDK4 kinase. The finding could pave the way for new therapies targeting this deadly subtype of breast cancer.
Researchers found that bexarotene reduced tumor burden by almost 50% and inhibited malignant tumor progression by about 50% in mice. The study suggests bexarotene is a potentially viable lung cancer prevention candidate.
Researchers found that human kidney cancer cells lacking the tumor suppressor gene Von Hippel Lindau were more sensitive to CCI-779 due to high levels of hypoxia-inducible factor (HIF). The study identified a test to predict which patients will benefit from receiving CCI-779, potentially helping 20,000 kidney cancer patients annually.
Researchers at St. Jude Children's Research Hospital have made significant progress in treating Acute Lymphoblastic Leukemia (ALL), with a reported 90% cure rate. The improvements are attributed to the effective use of existing drugs, genetic technologies, and personalized treatments.
A new clinical trials method is proposed to improve patient care by incorporating Bayesian approaches in trial design. The frequentist statistical method used today is considered too rigid and limits innovation, whereas the Bayesian approach allows for continuous updating based on interim results.
A study of primary-care patients found that genetic variations can affect the metabolism of common medications, potentially leading to adverse reactions. The researchers suggest that applying pharmacogenetics in primary-care practices could reduce costs by minimizing unnecessary prescriptions and hospital treatments.
Researchers found that combining trastuzumab, an antibody targeting HER2 protein, with immune-stimulating agents like IL-12 can activate the immune system to attack tumor cells more effectively. This combination may improve treatment outcomes for breast cancer patients.
A large study of over 4000 participants found no association between statin use and reduced risk of colorectal cancer. The researchers noted that if statins strongly reduced the risk, any cholesterol-lowering drug would likely show some reduction in risk due to shared users.
A meta-analysis of randomized controlled trials found that statins did not reduce the incidence of cancer or cancer death. The study evaluated 86,936 participants and 26 trials, with no reductions noted for specific types of cancer.
Two new studies uncover significant associations between certain autoimmune disorders and an increased risk of non-Hodgkin lymphoma. Meanwhile, a separate study suggests that consuming carbonated soft drinks may decrease the risk of esophageal adenocarcinoma, contrary to previous findings.
Researchers designed a new trinuclear platinum compound with enhanced cellular absorption, which targets cancer cells and reduces resistance. The novel compound's non-covalent interactions minimize side effects and improve its effectiveness against common human cancers.
J. Virgil Waggoner is being recognized by the Chemical Heritage Foundation for his outstanding contributions to the petrochemical industry, as well as his commitment to education and community service. He will receive the Petrochemical Heritage Award at the opening of the 31st annual NPRA International Petrochemical Conference.
The study reveals that the EBNA3C protein recruits a complex to degrade the retinoblastoma protein (Rb), leading to uncontrollable cell proliferation. This finding holds promise for developing new treatments for EBV-associated B cell lymphomas and other blood cancers.
A recent study by Mayo Clinic researchers found that only about 4.5% of aggressive kidney tumors express KIT, a receptor kinase tyrosine, and no mutations were detected in most cases. This suggests that imatinib therapy may not be effective for these patients, despite previous studies suggesting its potential benefits.
A study found that informational campaigns alone may not be enough to increase participation in cancer clinical trials among black and Asian American patients. Lack of awareness about trial costs being covered by insurance is a significant barrier to participation, especially among those with lower incomes and education levels.
Researchers studied early heart development using Drosophila genetics, finding that Slit and Robo proteins play a critical role in proper alignment of heart tube cells. This misalignment can lead to observed heart defects, and the study may soon be applied to develop diagnostic tests for congenital heart defects.
Women with the CYP2D6 genetic variant were more likely to experience breast cancer recurrence when treated with tamoxifen. Researchers also found that this group was less likely to suffer from hot flashes, which may predict the gene variation.
Researchers at the Burnham Institute, along with partners from six institutions, are working on a NCI-funded project to develop an accurate early-stage diagnosis method for prostate cancer. The goal is to identify specific gene products indicative of the disease's clinical behavior.
Researchers found encouraging preliminary findings in four patients with CLL who improved after taking EGCG, an extract of green tea. However, more studies are needed to determine the optimal dose and side effects before recommending widespread use.
Researchers found marked improvement in chronic myeloid leukemia and acute lymphocytic leukemia patients treated with AMN107. The drug, taken in pill form, outperforms Gleevec by up to 50 times in shutting down cancer-causing tyrosine kinase.
A new study conducted at Ohio State University found that combining the immune substances IL-12 and interferon is safe for patients with advanced cancer. The treatment combination was shown to stop disease progression in five patients for at least six months, with no serious side effects reported.
A study by Northwestern University found that a major sales promotion effort by AstraZeneca and TAP Pharmaceuticals led to significant income increases for urologists. The switch to Average Sales Price-based Medicare reimbursement is expected to decrease oncologists' revenue by 8%.
Researchers found that chemotherapy with doxorubicin and cisplatin extended disease-free survival by 50% and overall survival by 13% compared to radiation therapy. Serious side effects were more common in the chemotherapy group, but a new regimen may be less toxic.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
Researchers at Johns Hopkins Medicine have identified a new therapeutic target for drugs to treat multiple sclerosis (MS) and other autoimmune diseases. By targeting dendritic cells, the researchers hope to stop faulty immune responses at an upstream level.
New research suggests that Herceptin may be cost-effective for certain sub-groups of patients with early breast cancer, but its use as adjuvant therapy could impose a significant financial burden on healthcare systems. The study estimates that the cost of providing Herceptin treatment in Belgium would be around €25.5 million per year.
A University of Minnesota study reveals that nearly 20% of childhood cancer survivors experience physical limitations and trouble performing daily activities. Survivors of brain and bone cancers are most affected, with many reporting difficulties attending work or school.
UC Davis researchers have discovered a genetic switch, Ku86, involved in cells' response to radiation therapy. The switch, when turned off, enhances the effectiveness of radiation therapy with less toxicity than current radiosensitizing drugs.
Researchers investigate compounds like thalidomide, arsenic, and insecticide-derived drugs for their potential to treat solid tumors and various types of cancers. These novel approaches aim to overcome resistance to existing treatments and reduce adverse effects associated with hormonal ablation therapy.
Researchers have discovered a protein, RAR1, critical for response to retinoid treatment, which is resistant to this class of drugs. By triggering RAR1 protein expression in cancer cells, sensitivity can be restored, offering new hope for lung cancer patients.
A new combination treatment for glioblastoma has been found to improve survival rates without negatively affecting patients' quality of life. The study, which involved 573 patients, found no significant differences in six out of seven health-related quality of life measures after three months.
A follow-up study to the NSABP Breast Cancer Prevention Trial confirms tamoxifen's effectiveness in reducing invasive and noninvasive breast cancer risk. The study found a 43% reduction in invasive breast cancer risk and a 37% reduction in noninvasive breast cancer risk.
Researchers at VCU Massey Cancer Center have successfully combined two novel drugs to treat breast cancer, achieving profound tumor cell death in a short period. The combination of UCN-01 and a MEK 1/2 inhibitor shows great potential for treating various types of cancer.
Researchers at UCLA have identified a molecular signature that can predict which patients with glioblastoma, a deadly brain cancer, are likely to respond to drug therapy. The discovery involves the presence of a mutant protein and a tumor suppressor protein called PTEN.
PET imaging with FDG is a powerful tool in determining the extent of spread of reproductive system cancers, particularly when other conventional tests are ambiguous. Studies have shown its high sensitivity in detecting nodal disease in cervical cancer and its superior detection abilities compared to CT or MRI in recurrent ovarian cancer.
Researchers found that people with Barrett's esophagus who regularly took NSAIDs like aspirin had a one-third reduced risk of esophageal adenocarcinoma. The protective effect wears off quickly, and the risk reverts back to never users after three years of discontinuing use.
Researchers found that drugs inhibiting MEK selectively inhibit growth of cancer cells with BRAF and RAS mutations, leading to clinical trials for patients with melanoma, colon, breast, and lung cancers. The study identifies a novel class of targeted therapies, which may be more effective and less toxic than traditional chemotherapies.
A study of 304 recently diagnosed cancer patients found that 57% of pre-diagnosis CAM users continued to use it after diagnosis, with post-diagnosis use being almost universally helpful. The study highlights the importance of addressing psychosocial needs and communication barriers in cancer care.
A new drug developed at UC Davis in collaboration with Finnish researchers shows promise in preventing breast cancer and treating post-menopausal vaginal atrophy. The study found that the drug inhibited breast cancer development by 95% in mice, suggesting a potential benefit for millions of women.
Lung cancer researchers are exploring new approaches to prevent and treat the disease, including nicotine vaccines that can reduce tobacco dependence. Additionally, studies on chemoprevention strategies aim to identify populations at high risk for lung cancer and design effective prevention methods.
Researchers have identified compounds that can reduce cancer incidence, including thiazolidinediones for type-2 diabetes patients. Synthetic triterpenoids like CDDO-Im also show potent protection against liver tumors.
Researchers have unveiled a new technique to characterize binding interactions of multivalent molecules designed for targeted drug delivery in cancer treatment. This method, using atomic force microscopy, shows promise for optimizing binding affinity and designing better antibodies.
Researchers developed nanoparticles that can target and deliver drugs to prostate cancer cells using aptamers, achieving highly specific and efficient tumour targeting. The bioconjugates successfully adhered to PSMA-positive prostate cancer cells and were rapidly internalised into the targeted cells.
A survey of 1,139 smoking patients found that women are more likely than men to believe nicotine causes cancer and feel guilty about their smoking habit. Women also reported a higher fear of gaining weight and managing stress without cigarettes when quitting, highlighting the need for targeted tobacco cessation programs.
Researchers at Johns Hopkins Kimmel Cancer Center have found hormone therapy will not diminish the value of radiation for prostate cancer. Additionally, a leukemia drug shows modest benefits in suppressing PSA levels for some men with localized prostate cancer.